Siltuximab
Based on 4 publication(s) in Google Scholar
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : ≥99.0%
- CAS 番号: 541502-14-1
- 分子量:144.98 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Siltuximab
More-
Cell Imaging/Staining
-
IF
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IL-6/IFNb2
体内実験
Siltuximab (intraperitoneal injection; 20 mg/kg; twice per week; 6 w) inhibits the growth of MCF-7 tumor in xenograft model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CD-1 nu/nu mice injected with H1650 (adenocarcinoma), H322 (adenocarcinoma), or H157 (squamous) cells[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; 10 mg/kg; 3 times per week
-
Result:Repressed PY-STAT3 levels stimulated by IL-6 in H322 cells.
Repressed PY-STAT3 levels in H1650 cells.
Inhibited the growth of tumors with H322 and CAF cells.
Inhibited the growth of tumors with H1650 and CAF cells.
-
Animal Model:Female NOD-SCID mice with MCF-7 tumor[4]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection; 20 mg/kg; twice per week; 6 weeks
-
Result:Blocked MCF-7 engraftment, induced regressions in 90% of tumors.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IL-6 Protein, Human (HY-P7044) can bind Siltuximab. The EC50 for this effect is 4.04 ng/mL. -
Flow cytometric analysis of 1.5×106 Siha cells with Siltuximab (HY-P9956, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 541502-14-1
-
性状 Liquid
-
分子量 144.98 kDa
-
Color Colorless to light yellow
-
SMILES
[Siltuximab]
-
別名
CNTO-328
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Combining Microfluidic Assessment with Encoded Hydrogel Microparticle-Based Immunoassay for Anti-Interleukin Drug Repurposing of Pulmonary Fibrosis Therapy. [Abstract]2025 Sep 16;19(36):32361-32373. PMID: 40903905
Siltuximab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Representative images of fibrosis-induced spheroids subjected to microfluidic deformation analysis, comparing untreated control, antifibrotic drug NTD, and anti-interleukin drugs TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.
Siltuximab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Confocal fluorescence images showing the expression of collagen-1 and α-SMA in spheroids treated with NTD, TCZ, STX, DUP, and TRA. Mab (5 μg/mL, 1 d) were added, Scale bars indicate 100 μm.
-
J Transl Med
Esophageal microbial dysbiosis impairs mucosal barrier integrity via toll-like receptor 2 pathway in patients with gastroesophageal reflux symptoms. [Abstract]2024 Dec 24;22(1):1145. PMID: 39719586 -
Brain Behav Immun
A gut-adipose-nerve axis mediates inulin protection against Western diet-induced somatosensory dysfunction. [Abstract]2026 May 4:137:106795. PMID: 42092466 -
Esophagus
Acid bile salt induces esophageal mucosal barrier dysfunction through miR-146a-5p-KYNU pathway in gastroesophageal reflux disease. [Abstract]2026 Apr;23(2):419-433. PMID: 41703371
プロトコル
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011 Sep 15;71(13):1455-65. [Content Brief]
[2]. Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12. [Content Brief]
[3]. Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9(7):974-982. [Content Brief]
[4]. Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press). 2016 Feb 3;8:13-27. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)